PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Samsara Inc. (IOT)
33.600.80 (-2.33%)
33.44 - 34.57
31.40 - 61.90
7.61M / 5.95M (Avg.)
-152.73 | -0.22
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
16.31%
Revenue growth above 1.5x BRZE's 5.65%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
17.79%
Gross profit growth above 1.5x BRZE's 0.44%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
0.79%
EBIT growth below 50% of BRZE's 11.99%. Michael Burry would suspect deeper competitive or cost structure issues.
0.79%
Operating income growth under 50% of BRZE's 11.99%. Michael Burry would be concerned about deeper cost or sales issues.
-149.00%
Negative net income growth while BRZE stands at 8.02%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-147.93%
Negative EPS growth while BRZE is at 6.45%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-147.93%
Negative diluted EPS growth while BRZE is at 6.45%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
1.08%
Share count expansion well above BRZE's 0.70%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
1.08%
Diluted share count expanding well above BRZE's 0.70%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-452.24%
Negative OCF growth while BRZE is at 290.76%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-615.27%
Negative FCF growth while BRZE is at 40.13%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
55.91%
10Y revenue/share CAGR under 50% of BRZE's 179.34%. Michael Burry would suspect a lasting competitive disadvantage.
55.91%
5Y revenue/share CAGR under 50% of BRZE's 179.34%. Michael Burry would suspect a significant competitive gap or product weakness.
55.91%
3Y revenue/share CAGR under 50% of BRZE's 179.34%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
46.47%
10Y OCF/share CAGR under 50% of BRZE's 17395.14%. Michael Burry would worry about a persistent underperformance in cash creation.
46.47%
Below 50% of BRZE's 17395.14%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
46.47%
3Y OCF/share CAGR under 50% of BRZE's 17395.14%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
-34.27%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-34.27%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-34.27%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
173.60%
Below 50% of BRZE's 474.91%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
173.60%
Below 50% of BRZE's 474.91%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
173.60%
Below 50% of BRZE's 474.91%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
40.48%
AR growth well above BRZE's 36.39%. Michael Burry fears inflated revenue or higher default risk in the near future.
-17.95%
Both reduce inventory yoy. Martin Whitman suspects a broader move to lean operations or industry slowdown in demand.
2.87%
Asset growth at 50-75% of BRZE's 5.47%. Martin Whitman questions if the firm is lagging expansions or if the competitor invests more aggressively.
-4.79%
We have a declining book value while BRZE shows 0.60%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-4.22%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
20.73%
R&D growth drastically higher vs. BRZE's 4.16%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
13.94%
We expand SG&A while BRZE cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.